CRMD
Price
$12.65
Change
-$0.29 (-2.24%)
Updated
Sep 15 closing price
Capitalization
944.31M
51 days until earnings call
HOTH
Price
$1.82
Change
+$0.22 (+13.75%)
Updated
Sep 15 closing price
Capitalization
24.13M
Interact to see
Advertisement

CRMD vs HOTH

Header iconCRMD vs HOTH Comparison
Open Charts CRMD vs HOTHBanner chart's image
CorMedix
Price$12.65
Change-$0.29 (-2.24%)
Volume$2.33M
Capitalization944.31M
Hoth Therapeutics
Price$1.82
Change+$0.22 (+13.75%)
Volume$2.87M
Capitalization24.13M
CRMD vs HOTH Comparison Chart in %
Loading...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRMD vs. HOTH commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Buy and HOTH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (CRMD: $12.65 vs. HOTH: $1.82)
Brand notoriety: CRMD and HOTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 63% vs. HOTH: 274%
Market capitalization -- CRMD: $944.31M vs. HOTH: $24.13M
CRMD [@Biotechnology] is valued at $944.31M. HOTH’s [@Biotechnology] market capitalization is $24.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 1 FA rating(s) are green whileHOTH’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 1 green, 4 red.
  • HOTH’s FA Score: 1 green, 4 red.
According to our system of comparison, CRMD is a better buy in the long-term than HOTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 6 TA indicator(s) are bullish while HOTH’s TA Score has 6 bullish TA indicator(s).

  • CRMD’s TA Score: 6 bullish, 4 bearish.
  • HOTH’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CRMD and HOTH are a good buy in the short-term.

Price Growth

CRMD (@Biotechnology) experienced а -0.78% price change this week, while HOTH (@Biotechnology) price change was +23.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.45%. For the same industry, the average monthly price growth was +7.05%, and the average quarterly price growth was +34.61%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+3.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($944M) has a higher market cap than HOTH($24.1M). HOTH YTD gains are higher at: 143.283 vs. CRMD (56.173). CRMD has higher annual earnings (EBITDA): 52.3M vs. HOTH (-10.09M). CRMD has more cash in the bank: 191M vs. HOTH (9.01M). HOTH has less debt than CRMD: HOTH (21.3K) vs CRMD (435K). CRMD has higher revenues than HOTH: CRMD (121M) vs HOTH (0).
CRMDHOTHCRMD / HOTH
Capitalization944M24.1M3,917%
EBITDA52.3M-10.09M-519%
Gain YTD56.173143.28339%
P/E Ratio16.22N/A-
Revenue121M0-
Total Cash191M9.01M2,119%
Total Debt435K21.3K2,042%
FUNDAMENTALS RATINGS
CRMD vs HOTH: Fundamental Ratings
CRMD
HOTH
OUTLOOK RATING
1..100
729
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
2599
PRICE GROWTH RATING
1..100
4440
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HOTH's Valuation (28) in the Pharmaceuticals Major industry is in the same range as CRMD (57) in the Medical Specialties industry. This means that HOTH’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for HOTH (100) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew somewhat faster than HOTH’s over the last 12 months.

CRMD's SMR Rating (25) in the Medical Specialties industry is significantly better than the same rating for HOTH (99) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew significantly faster than HOTH’s over the last 12 months.

HOTH's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as CRMD (44) in the Medical Specialties industry. This means that HOTH’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as HOTH (100) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew similarly to HOTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRMDHOTH
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
83%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IROH10.881.92
+21.43%
Iron Horse Acquisitions Corp
GNFT4.330.09
+2.00%
Genfit SA
SBRA19.190.14
+0.73%
Sabra Health Care REIT
PCAR102.17-0.34
-0.33%
PACCAR
XPEL34.32-0.36
-1.04%
XPEL

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-2.24%
MURA - CRMD
38%
Loosely correlated
-0.48%
ARTL - CRMD
33%
Poorly correlated
-1.13%
RLYB - CRMD
32%
Poorly correlated
-1.23%
XLO - CRMD
31%
Poorly correlated
+2.05%
HOTH - CRMD
30%
Poorly correlated
+13.75%
More

HOTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, HOTH has been loosely correlated with TIL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HOTH jumps, then TIL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HOTH
1D Price
Change %
HOTH100%
+13.75%
TIL - HOTH
34%
Loosely correlated
+6.97%
PPTDF - HOTH
32%
Poorly correlated
N/A
AIM - HOTH
30%
Poorly correlated
-1.92%
CRMD - HOTH
30%
Poorly correlated
-2.24%
OGEN - HOTH
28%
Poorly correlated
+4.96%
More